Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Rockland and LIMR Expand Licensing and Commercialization Relationship

Published: Tuesday, October 30, 2012
Last Updated: Tuesday, October 30, 2012
Bookmark and Share
Rockland will market established technologies including the CellCountEZ®, OxPhos™, RadDose™ and the Intracellular ThiolEZ™ assays.

Rockland Immunochemicals Inc., has announced the expansion of a licensing and commercialization relationship with Lankenau Institute for Medical Research (LIMR) through its business development subsidiary LIMR Development, Inc. (LDI). Instrumental in advancing this relationship was Carl Leighton of Wildwood Capital.

According to a new agreement, Rockland Immunochemicals will market established technologies including the CellCountEZ®, OxPhos™, RadDose™ and the Intracellular ThiolEZ™ assays.

Detailed product information is provided at www.limrdevelopment.com and www.rockland-inc.com/limr-collaboration.

George Prendergast, PhD, President and CEO of LIMR stated: “We have been very pleased with our partnership with Rockland and are looking forward to continued success within this expanded relationship.”

"LIMR's independent research encompassing cancer and inflammation elegantly enhances Rockland's antibody portfolio and technology platform. It is my belief that the new products included in our expanded licensing and commercialization agreement will enhance our ability to bring unique scientific opportunities to the global research community," commented James Fendrick, President and CEO of Rockland Immunochemicals.

Included in the additional product lines will be the CellCountEZ® assay measuring metabolically active cells while simultaneously quantifying cell death to determine cell viability, cell toxicity or cellular proliferation.

The OxPhos™ assay is capable of determining the cellular glutathione recycling capacity in tissue culture as well as that of whole blood, thus providing insight into oxidative stress during the aging process, antioxidant levels upon delivery of chemotherapy regime and toxicology.

The RadDose™ assay is used for the measurement of ionizing radiation dose rates, while the Intracellular ThiolEZ™ assay is capable of determining total intracellular thiols, including glutathione and cysteine, as a means of investigating the aging, oxidative stress, antioxidant, chemotherapy response and toxicology processes.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Rockland Awarded SBIR Funding
Company awarded grant to develop antibody-based point of care device for the diagnosis of sickle cell disease.
Tuesday, September 09, 2014
Rockland Immunochemicals Expands into 60,000 Square Foot Facility
Company expands laboratories to keep pace with growth.
Thursday, May 29, 2014
Rockland Immunochemicals Awarded Phase I SBIR Funding
SBIR grant to develop nanoprobes for in vivo imaging of cancer cells and tumors.
Tuesday, October 22, 2013
Rockland Immunochemicals Acquires Epi-Plus® Product Line
Rockland Immunochemicals, Inc. announced the acquisition of the Epi-Plus® antibody product line from 21st Century Biochemicals, Inc.
Tuesday, April 09, 2013
Rockland Immunochemicals Awarded Phase II SBIR Funding
Company receives grant for 1 million dollars to develop Akt/mTOR signaling pharmacodynamics assay.
Tuesday, October 16, 2012
Rockland Immunochemicals and LDI Form Antibody Commercialization Partnership
Rockland will market LDI’s entire portfolio of LIMR monoclonal and polyclonal antibodies.
Monday, April 23, 2012
Rockland Immunochemicals and Emory University Sign Master Reagent Agreement
Rockland and Emory collaborate to develop novel antibodies and antibody based tools for cancer, cell signaling and chromatin research.
Friday, January 28, 2011
Rockland Immunochemicals Awarded Phase I Funding to Develop Generic Antibodies for the Treatment of Cancer
Rockland Immunochemicals Inc. have received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop generic antibodies “biosimilars” for the treatment of cancer.
Thursday, November 04, 2010
Scientific News
Bacteria Use Ranking Strategy to Fight Off Viruses
Researchers have explained why microbes store virus confrontation information sequentially, with most recent attacks first.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Reprogramming Lymph Nodes to Fight MS
Bioengineers work to reprogram lymph node function to fight multiple sclerosis.
Antibodies Block Norovirus’ Entrance into Cells
Scientists have uncovered a mechanism in the human body that targets and successfully blocks noroviruses.
Probe Detects Histone Modifications in Cells
Scientists have developed an antibody probe that can be used to monitor the dynamics of histone modification.
Gut Pathogens Thrive on Body's Tissue-Repair Mechanism
Researcher have discovered that harm caused by pathogens in the intestinal tract benefit from immune system response to damaged intestinal lining.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Arms Race with a Superbug
Scientists have discovered that increased risk of superbug infection can be directly casued by immune system response to invading bacteria.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!